We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

dinsdag 10 oktober 2017

The Lancet: [Articles] Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-c...

[Articles] Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Pembrolizumab has meaningful clinical activity in patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma. Enrolment to expanded cohorts of those subtypes is ongoing to confirm and characterise the activity of pembrolizumab.
Read more

[Comment] PD-1 inhibition in bone sarcoma and soft-tissue sarcoma
Sarcoma is a highly heterogeneous malignancy (>50 histological subtypes), for which active treatments beyond doxorubicin and ifosfamide are restricted to only some histological subtypes.1 Therefore, treatment selection in advanced disease is mainly based on histological subtype, although this approach has limitations in the perioperative setting.2
Read more

[News] Insulin analog linked to breast cancer risk
Long-term use of the insulin analog glargine is positively associated with breast cancer risk in patients with type 2 diabetes, according to recent findings from a population-based study.
Read more

[News] Maintenance rituximab in mantle-cell lymphoma
Maintenance rituximab therapy improves event-free survival compared with observation in patients with mantle-cell lymphoma and is associated with a low frequency of major infection after transplantation, according to a new study.
Read more

[Articles] Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial
We noted no survival benefit in men with metastatic castration-resistant prostate cancer with the addition of custirsen to cabazitaxel and prednisone treatment. Cabazitaxel and prednisone remains the standard of care for patients with metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy.
Read more